<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003294</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066227</org_study_id>
    <secondary_id>P30CA016056</secondary_id>
    <secondary_id>RPCI-DS-97-14</secondary_id>
    <secondary_id>NCI-G98-1410</secondary_id>
    <nct_id>NCT00003294</nct_id>
  </id_info>
  <brief_title>Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer</brief_title>
  <official_title>Initial Clinical Evaluation of the Combination of Paclitaxel and Carboplatin With Modulation of Toxicity With GCSF and Amifostine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells&#xD;
      from the side effects of chemotherapy. Colony-stimulating factors such as filgrastim may&#xD;
      increase the number of immune cells found in bone marrow or peripheral blood and may help a&#xD;
      person's immune system recover from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of&#xD;
      paclitaxel plus carboplatin given with amifostine and filgrastim in treating patients with&#xD;
      recurrent or metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Establish the maximum tolerated dose of a paclitaxel and carboplatin&#xD;
      combination modulated by amifostine and filgrastim (G-CSF) in patients with recurrent or&#xD;
      metastatic cancer. II. Define the dose limiting toxicity of this combination in these&#xD;
      patients. III. Observe any antitumor responses in patients treated with this combination.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of paclitaxel. Patients receive a 10 minute infusion&#xD;
      of amifostine followed by paclitaxel given intravenously over 3 hours followed by carboplatin&#xD;
      given over 30 minutes. Filgrastim (G-CSF) is given subcutaneously daily for up to 10 days by&#xD;
      self administration starting the following day. Treatment repeats every 28 days for at least&#xD;
      3 courses unless disease progression or unacceptable toxicity occurs. Patients who develop&#xD;
      dose-limiting toxicity (DLT) on a given course receive one dose level lower on the next and&#xD;
      subsequent courses. Patients with stable disease may continue treatment for as long as&#xD;
      benefit is shown. In the absence of DLT in the first 3 patients treated, subsequent cohorts&#xD;
      of 3 patients each receive escalating doses of paclitaxel on the same schedule. If DLT occurs&#xD;
      in 1 of 3 patients at a given dose level, then 3 additional patients are added at that dose.&#xD;
      If DLT occurs in 1 additional patient, this dose is the maximum tolerated dose (MTD); if DLT&#xD;
      occurs in more than 2 patients, then 3 additional patients are added at the previous dose. If&#xD;
      DLT occurs in no more than 2 of 6 patients, this dose is considered the MTD. At any dose, 3&#xD;
      cases of DLT leads to discontinuation of recruitment at that dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 24 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">April 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven recurrent or metastatic malignant disease&#xD;
        not amenable to curative surgery, radiotherapy, conventional chemotherapy, or&#xD;
        investigational therapy of higher priority Priority given to patients with lung cancer or&#xD;
        cancers with tumors easily available for biopsy No CNS disease unless stable post radiation&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:&#xD;
        At least 3 months Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 100,000/mm3&#xD;
        Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL&#xD;
        Creatinine clearance at least 50 mL/min Cardiovascular: Systolic blood pressure at least 90&#xD;
        mm Hg No severe heart decompensation No clinically significant cardiac arrhythmia on EKG No&#xD;
        inability to tolerate bradycardia Other: No active, uncontrolled infection No nonmalignant&#xD;
        systemic disease Not pregnant or nursing Effective contraception required of fertile&#xD;
        patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immune stimulating agents&#xD;
        Chemotherapy: At least 3 weeks since chemotherapy (6 weeks since nitrosourea or mitomycin)&#xD;
        and recovered No prior paclitaxel or carboplatin No concurrent chemotherapy Endocrine&#xD;
        therapy: No concurrent hormone therapy Radiotherapy: At least 3 weeks since radiotherapy to&#xD;
        major bone marrow bearing areas and recovered Concurrent radiotherapy allowed for vital&#xD;
        indications or pain relief Surgery: At least 3 weeks since surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary N. Schwartz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2004</study_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2011</last_update_posted>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

